These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 8582238)
61. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. Scott IS; Morris LS; Bird K; Davies RJ; Vowler SL; Rushbrook SM; Marshall AE; Laskey RA; Miller R; Arends MJ; Coleman N J Pathol; 2003 Oct; 201(2):187-97. PubMed ID: 14517835 [TBL] [Abstract][Full Text] [Related]
62. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). Guillaud P; du Manoir S; Seigneurin D Anal Cell Pathol; 1989 Feb; 1(1):25-39. PubMed ID: 2488698 [TBL] [Abstract][Full Text] [Related]
63. Proliferative cell indices measured by DNA flow cytometry in node-negative adenocarcinomas of breast: accuracy and significance in cytokeratin-stained archival specimens. Frei JV; Rizkalla K; Martinez VJ Mod Pathol; 1994 Dec; 7(9):925-9. PubMed ID: 7534400 [TBL] [Abstract][Full Text] [Related]
64. [Flow cytometric analysis of cell proliferation kinetics using the anti-BrdUrd antibody]. Sasaki K; Murakami T; Takahashi M Gan To Kagaku Ryoho; 1989 Jul; 16(7):2338-44. PubMed ID: 2751315 [TBL] [Abstract][Full Text] [Related]
65. Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Landberg G; Roos G Cancer Res; 1991 Sep; 51(17):4570-4. PubMed ID: 1678682 [TBL] [Abstract][Full Text] [Related]
68. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714 [TBL] [Abstract][Full Text] [Related]
69. Cytokinetic analysis of lung cancer by bromodeoxyuridine labeling of cytology specimens. ten Velde GP; Schutte B; Reijnders MM; Bosman FT; Blijham GH Cytometry; 1989 Nov; 10(6):807-10. PubMed ID: 2582973 [TBL] [Abstract][Full Text] [Related]
70. [Preliminary study by flow cytometry of the cell cycle and DNA quantification in cytokeratin-positive cells in tumors of the head and neck]. Górriz C; González FM; Castejón R; García-Berrocal JR; Durántez A; Vargas JA Acta Otorrinolaringol Esp; 1999 May; 50(4):296-304. PubMed ID: 10431079 [TBL] [Abstract][Full Text] [Related]
71. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690 [TBL] [Abstract][Full Text] [Related]
73. Flow cytometric evaluation of Ki67 proliferative antigen in primary breast cancer. Niezabitowski A; Lackowska B; Ryś J; Gruchała A; Szklarski W; Stelmach A; Wasilewska A; Kruczak A; Swiatkiewicz I Pol J Pathol; 1995; 46(1):17-22. PubMed ID: 7780692 [TBL] [Abstract][Full Text] [Related]
74. [A significance of dual parameter flow cytometric DNA analysis using the anti-keratin antibody]. Ishikawa H; Tagawa Y; Miyashita K; Yokota M; Yasutake T; Okada D; Kunisaki T; Tomita M Hum Cell; 1989 Mar; 2(1):70-3. PubMed ID: 2485104 [TBL] [Abstract][Full Text] [Related]
75. Development of a flow cytometric method to determine DNA ploidy of oesophageal cancer cells obtained by forceps biopsy samples during oesophago-gastro-duodenoscopy. Rickes S; Hauptmann S; Flath B; Abbenseth R; Zwiebel FM; Possinger K Onkologie; 2003 Feb; 26(1):32-7. PubMed ID: 12624515 [TBL] [Abstract][Full Text] [Related]
76. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Lehmann J; Retz M; Nürnberg N; Schnöckel U; Raffenberg U; Krams M; Kellner U; Siemer S; Weichert-Jacobsen K; Stöckle M Cancer; 2004 Oct; 101(7):1552-62. PubMed ID: 15378494 [TBL] [Abstract][Full Text] [Related]
77. Heterogeneity in proliferation markers in colorectal cancer. Kressner U; Lindmark G; Gerdin B; Pahlman L; Glimelius B Anticancer Res; 1995; 15(6B):2755-61. PubMed ID: 8669859 [TBL] [Abstract][Full Text] [Related]
78. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Atula S; Grenman R; Syrjänen S Exp Cell Res; 1997 Aug; 235(1):180-7. PubMed ID: 9281367 [TBL] [Abstract][Full Text] [Related]
79. Evaluation of proliferating cells in acute leukemia with antibodies to proliferating cell nuclear antigen and Ki-67 monoclonal antibodies. Inoue T; Yamane T; Park K; Im T; Tatsumi N; Okuda K Arch Pathol Lab Med; 1993 Oct; 117(10):969-72. PubMed ID: 8105766 [TBL] [Abstract][Full Text] [Related]
80. Prognostic value of cell proliferation markers, tumour suppressor proteins and cell adhesion molecules in primary squamous cell carcinoma of the larynx and hypopharynx. Liu M; Lawson G; Delos M; Jamart J; Chatelain B; Remacle M; Marbaix E Eur Arch Otorhinolaryngol; 2003 Jan; 260(1):28-34. PubMed ID: 12520353 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]